Yarrow Bioscience (YARW) Research & Development (2017 - 2026)
Yarrow Bioscience's (YARW) quarterly Research & Development came in at $817000.0 in Q1 2026, down 86.66% YoY from $6.1 million in Q1 2025, and down 83.26% on a QoQ basis from $4.9 million in Q2 2025.
Yarrow Bioscience (YARW) Research & Development (2017 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 10 years of Research & Development data on file, last reported at $817000.0 in Q1 2026.
- Quarterly Research & Development fell 86.66% year-over-year to $817000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.5 million (down 35.54% YoY) and the FY2025 annual result came in at $19.2 million, down 37.84% from the prior year.
- Research & Development declined to $817000.0 in Q1 2026, from $4.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $10.2 million in Q3 2024 to a low of $817000.0 in Q1 2026.
- A 5-year average of $5.2 million and a median of $4.5 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development surged 220.34% — and 2026, when it slumped 86.66%.
- Tracing YARW's Research & Development over 5 years: stood at $4.3 million in 2022, then fell by 29.35% to $3.0 million in 2023, then surged by 220.34% to $9.7 million in 2024, then plunged by 49.6% to $4.9 million in 2025, then sank by 83.26% to $817000.0 in 2026.
- The last three Research & Development figures came in at $817000.0 (Q1 2026), $4.9 million (Q2 2025), and $6.1 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - | 788,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 788,000.00 |
| Mar 31, 2026 | 817,000.00 |
| Jun 30, 2025 | 4.88 Mn |
| Mar 31, 2025 | 6.12 Mn |
| Dec 31, 2024 | 9.68 Mn |
| Sep 30, 2024 | 10.25 Mn |
| Jun 30, 2024 | 7.31 Mn |
| Mar 31, 2024 | 3.71 Mn |
| Dec 31, 2023 | 3.02 Mn |
| Sep 30, 2023 | 3.32 Mn |
| Jun 30, 2023 | 7.23 Mn |
| Mar 31, 2023 | 2.73 Mn |
| Dec 31, 2022 | 4.28 Mn |
| Sep 30, 2022 | 5.55 Mn |
| Jun 30, 2022 | 4.11 Mn |
| Mar 31, 2022 | 4.45 Mn |
| Dec 31, 2021 | 4.32 Mn |
| Sep 30, 2021 | 5.92 Mn |
| Jun 30, 2021 | 5.05 Mn |
| Mar 31, 2021 | 4.26 Mn |